Chronic Indomethacin Treatment Enhances the Portal-systemic Collateral Vascular Response to Vasopressin in Bile-duct Ligated Rats  by Huang, Hui-Chun et al.
J Chin Med Assoc • December 2007 • Vol 70 • No 12 521
Introduction
Liver cirrhosis with portal hypertension is one of the
most disastrous conditions related to chronic hepatic
injury. As portal pressure elevates, portal-systemic col-
laterals develop gradually to diverse blood flow from the
portal system.1 Rupture of the collaterals, especially gas-
troesophageal varices, leads to high morbidity and mor-
tality rates. To control variceal hemorrhage, vasopressin
has been used in past decades by virtue of its splanchnic
vasoconstrictive effect with subsequently decreased
portal venous inflow and portal pressure.2 In addition,
vasopressin exerts a direct vasoconstrictive effect on
portal-systemic collaterals.3 However, previous studies
in portal hypertensive animals found worse splanchnic
vascular contractile response to vasoconstrictors than
that of normal ones.4,5 Survey on portal hypertensive
animals and cirrhotic patients further demonstrated 
a less prominent portal hypotensive effect of vasopressin
during acute hemorrhage as compared with that during
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stable condition,6,7 that is, the so-called splanchnic
hyposensitivity.
It has been reported that indomethacin attenuates
vascular hyporesponsiveness to various vasoconstric-
tors4,5 associated with portal hypertension, suggesting
the participation of prostanoids in the mechanism. The
ability of indomethacin to ameliorate splanchnic hypo-
responsiveness to terlipressin, a long-acting vasopressin
analog, in hemorrhage-transfused cirrhotic rats further
supports its role in splanchnic hyposensitivity of cir-
rhotic rats during acute hemorrhage.8 In the collateral
vascular bed, the contractile reactiveness to vasopressin
is also enhanced by indomethacin preincubation in rats
with prehepatic portal hypertension and a relatively
high degree of portal-systemic shunting.3 However, the
effects of long-term indomethacin administration in
cirrhotic rats with a relatively lower number of collater-
als remain to be clarified. Therefore, we conducted this
study to survey the influences of chronic indomethacin
use on portal-systemic collateral vascular response to
vasopressin and the degree of shunting in bile-duct
ligated rats.
Methods
Experimental design
Two groups of rats that underwent bile-duct ligation
(BDL) received either indomethacin (5 mg/kg sub-
cutaneous injection, qd) or distilled water (control)
from the 36th to the 42nd day after operation. On the
43rd day after BDL, rats were anesthetized with keta-
mine hydrochloride (100 mg/kg intramuscularly), and
the body weight, mean arterial pressure, portal pres-
sure, and heart rate were measured.9 Two series of
experiments with the in situ collateral vascular perfu-
sion model were performed. In the first series (control,
n = 8; indomethacin, n = 8), cumulative concentration-
response curves of collateral vessels were determined
by graded final concentrations of arginine vasopressin
(AVP) in escalation with a constant flow rate (12 mL/
min). The final concentrations in perfusate were from
10−10 to 10−7 mol/L of AVP in perfusate. Each new
concentration was allowed to stabilize for 3 minutes
before the next higher concentration was added. In the
second series (control, n=7; indomethacin, n=9), flow-
pressure curves were obtained with Krebs solution to
assess the collateral vascular resistance (the slope of
the curve represents an index of portal-systemic shunting;
that is, the higher the slope [resistance], the lower the
relative number of portal-systemic shunting vessels).10
The flow rates were 6, 9, 12, 15 and 18 mL/min,
respectively.
Animal model
Male Sprague-Dawley rats weighing 240–270 g at the
time of surgery were used for experiments. The rats
were housed in plastic cages and allowed free access
to food and water. All rats were fasted for 12 hours
before the operation. In all experiments, the authors
adhered to the American Physiological Society Guiding
Principles for the Care and Use of Laboratory Animals.
Rats with secondary biliary cirrhosis were induced with
BDL followed by injecting formalin into the biliary
tree.11 Under ketamine anesthesia (100 mg/kg, intra-
muscularly), the common bile duct was exposed
through a midline abdominal incision, catheterized by
a PE-10 catheter, and doubly ligated with 3-0 silk. The
first ligature was made below the junction of the hepatic
ducts and the second ligature above the entrance of the
pancreatic duct. Then, 10% formalin (∼100 µL/100 g
body weight) was slowly injected into the biliary tree
above the first ligature to prevent the subsequent dilata-
tion of the ligated residual bile duct. The PE-10 catheter
was then removed and the ligatures tightened, followed
by section of the common bile duct between the liga-
tures. The rats were allowed to recover. A high yield of
secondary biliary cirrhosis were noted 5 weeks after
the ligation.12,13 To avoid coagulation defects, BDL
rats received weekly vitamin K injections (50 µg/kg,
intramuscularly).13
In situ perfusion preparation
The in situ perfusion system was performed as previ-
ously described.3,14,15 Both jugular veins were cannu-
lated with 16-gauge Teflon cannulas to ensure an
adequate outflow. A 18-gauge Teflon cannula inserted
in the distal superior mesenteric vein served as the
inlet of perfusate. To exclude the liver from perfusion,
the portal vein was tied, then the animal was trans-
ferred into a warm chamber (37 ± 0.5°C). Pneumo-
thorax was created to prevent the perfusate from
entering the left heart chambers. A non-recirculating
perfusion was then performed with Krebs solution
containing 3% wt/vol albumin (factor V bovine serum
albumin; Sigma Chemical Co., St Louis, MO, USA)
via the mesenteric cannula by a roller pump (model
505S; Watson-Marlow Limited, Falmouth, Cornwall,
UK). The perfusate was equilibrated with carbogen
gas (95% O2, 5% CO2) by a silastic membrane lung.16
A Spectramed DTX transducer (Spectramed Inc.,
Oxnard, CA, USA) attached to a Gould model RS
3400 recorder (Gould Inc., Cupertino, CA, USA)
was connected to a side arm proximal to the perfusion
cannula to record the pressure of the portal-systemic
collaterals. Only 1 concentration-response curve was
performed in each preparation. In each individual
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preparation, the contracting capability was challenged
with a 125-mmol/L potassium chloride solution at
the end of experiments.
Measurement of systemic and portal
hemodynamics
The right femoral artery was cannulated with a PE-50
catheter that was connected to a Spectramed DTX
transducer (Spectramed Inc.). Continuous recordings
of mean arterial pressure, heart rate and portal pres-
sure were performed on a multichannel recorder
(model RS 3400; Gould Inc.). The external zero refer-
ence was placed at the level of the mid-portion of the
rat. The abdomen was then opened with a midline
incision, and a mesenteric vein was cannulated with 
a PE-50 catheter connected to a Spectramed DTX
transducer. The abdominal cavity was closed and the
portal pressure recorded on the Gould model RS 3400
recorder.17
Drugs
Indomethacin, the reagents for preparing Krebs solu-
tion, and AVP were purchased from Sigma Chemical
Co. All solutions were freshly prepared on the days of
the experiments.
Data analysis
All results are expressed as mean ± standard error of
the mean. The changes in perfusion pressure (mmHg)
over baseline were calculated for each concentration
in each preparation. The concentration of AVP
exhibiting 50% of the maximal response (EC50) in
each preparation was calculated from sigmoid logistic
curves and expressed as negative log molar (–logM).
The flow-pressure curves were analyzed by linear
regression. Statistical analyses were performed using
independent Student’s t test. Results were considered
to be statistically significant at a 2-tailed p value of less
than 0.05.
Results
Hemodynamic effects of indomethacin
Table 1 shows the body weights and baseline hemo-
dynamic parameters of the indomethacin-treated and
control groups in 2 series of studies. The body weights,
mean arterial pressure, portal pressure, heart rates and
baseline perfusion pressure were similar between the
indomethacin and control groups in the first and second
series (p > 0.05).
Concentration-response relationships to AVP
Figure 1 depicts the concentration-response curves
obtained at a constant perfusion flow rate by the
cumulative addition of AVP into the perfusate for 
the 2 groups. As compared with the control group,
the indomethacin-treated group showed significantly
higher perfusion pressure to AVP at the concentra-
tion of 10–8 (indomethacin vs. control: 12.8 ± 1.7 vs.
7.5 ± 1.2 mmHg, p = 0.02) and 3 × 10–9 (7.6 ± 0.9 vs.
4.8 ± 0.8 mmHg, p = 0.027). The maximal perfusion
pressure change occurred at the concentration of
3 × 10–8 M. There was no significant difference in
EC50 between the 2 groups (indomethacin vs. control
[–logEC50]: 8.73±0.41 vs. 7.95±0.48, p=0.253). The
maximal pressure change of the portal-systemic collat-
eral vessels challenged with the 125-mmol/L potassium
chloride solution at the end of experiments was 22.9±
2.8mmHg for the indomethacin-treated group, higher
than that of the control group but without statistical
significance (19.1 ± 2.8 mmHg, p = 0.347).
Flow-pressure relationships
Figure 2 shows the flow-pressure relationship in the
perfused portal-systemic collaterals of indomethacin-
treated and control rats. The slope of the indomethacin-
treated group was not significantly different from that
of the control group (indomethacin vs. control:
0.99 ± 0.07 vs. 0.94 ± 0.04, p = 0.604).
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Table 1. Body weights and baseline hemodynamics in different groups*
n BW (g)
MAP HR (beats/ PorP Baseline 
(mmHg) min) (mmHg) PerP (mmHg)
Concentration-response curve study
INDO 8 382 ± 14 90 ± 6 260 ± 12 15.7 ± 1.0 16.1 ± 0.9
Control 8 346 ± 10 86 ± 4 254 ± 12 14.8 ± 0.4 15.4 ± 1.2
Flow-pressure curve study
INDO 9 363 ± 18 82.9 ± 3 258 ± 12 12.7 ± 0.6 15.7 ± 0.6
Control 7 366 ± 20 81.6 ± 5 254 ± 12 14.4 ± 0.4 17.3 ± 1.3
*There was no significant difference between the INDO and control groups. BW = body weight; MAP = mean arterial pressure; HR = heart rate; PorP = portal
pressure; Baseline PerP = baseline perfusion pressure; INDO = indomethacin.
Discussion
Indomethacin is a potent inhibitor of the cyclooxyge-
nases in the synthesis of various prostaglandins18 and
has been surveyed in various pathologic conditions.19
Many investigations find that the hyperdynamic cir-
culation of portal hypertension can be attenuated by
indomethacin.20 However, the systemic and portal
hemodynamics did not reach remarkable changes in
the present study. A similar finding has been reported
with daily injection of indomethacin (4 mg/kg/body
weight) for 2 days in rats after partial portal vein liga-
tion.21 The actual reason for the contradictory results
is not clear and might be due to different experimental
designs. However, vascular homeostasis maintained by
endogenous vasoactive substances might be considered.
For instance, unaltered blood pressure due to recip-
rocal interrelationship between nitric oxide (NO) and
prostaglandins has been observed22 and indomethacin
enhances interleukin-1β-induced nitrite release.23
In a previous study, indomethacin incubation sig-
nificantly potentiated the response of portal-systemic
collaterals to AVP in portal hypertensive rats. The
enhanced response to AVP by indomethacin suggested
the role of prostaglandin in the regulation of the portal-
systemic collateral circulation.3 We also found in the
current study that long-term use of indomethacin
improved the collateral vascular responsiveness to
AVP in BDL cirrhotic rats. Gastroesophageal varices
are the most prominent portal-systemic collaterals in
cirrhotic patients. Therefore, pharmacologic agents
that strengthen the collateral vascular response to vaso-
constrictors may contribute to a better hemostasis in
patients with variceal bleeding. However, the clinical
relevance of non-selective cyclooxygenase blockade is
questionable due to the concern of renal decompen-
sation: in cirrhotic patients, indomethacin for 7 con-
secutive days greatly impaired renal plasma flow,
creatinine clearance and serum creatinine.24 Selective
cyclooxygenase-2 inhibition seems promising since it
does not significantly impair kidney function in cirrhotic
rats with ascites.25 Recently, we have demonstrated with
various nitric oxide synthase (NOS) inhibitors that con-
stitutive rather than inducible NOS is involved in the
vascular response of portal-systemic collaterals of portal
hypertensive rats.26 Therefore, further survey with selec-
tive cyclooxygenase inhibitors might address the issue.
On the other hand, the degree of portal-systemic
shunting as indicated by the slope of the flow-pressure
curve was not significantly altered by chronic indome-
thacin treatment. Two possible origins of collateral ves-
sels in portal hypertensive models have been proposed:
passive dilatation of pre-existing venous channels27
and/or neovascularization.28,29 In terms of vascular
hyperemia with dilatation encountered in portal hyper-
tensive status, Fernandez et al had indicated that the
reduction of mesenteric arterial blood flow in portal
hypertensive rats was blunted to long-term indome-
thacin treatment (5 mg/kg/day, 7-day continuous
infusion) as compared with acute treatment.30 At the
same time, they also found an enhanced mesenteric
vascular response to a non-selective NOS inhibitor,
NG-nitro-L-arginine methyl ester.30 Since NO is another
endothelium-derived vasodilator that contributes to
the increased mesenteric arterial blood flow in portal
hypertensive status,31 enhanced NO may compensate
for the lack of vasodilatory prostaglandins in response to
chronic indomethacin administration. Regarding new
vessel formation, although indomethacin inhibited
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Figure 1. Concentration-response curves to arginine vasopressin
(AVP) in the portal-systemic collateral vascular beds of indomethacin-
and distilled-water (control)-treated bile duct-ligated rats, expressed
as absolute increase over baseline value.
Figure 2. Flow-pressure relationship in perfused portal-systemic
collateral vascular beds of indomethacin- and distilled-water 
(control)-treated bile duct-ligated rats.
neovascularization of rabbit cornea,32 a similar effect
was not found in portal-systemic collaterals. Since
NO has also been found to participate in the process
of neovascularization in portal hypertensive rats,28,29
the counter-regulation by NO under the setting of
prostaglandin synthesis inhibition should be consid-
ered, which deserves further evaluation.
Long-term indomethacin administration did not
elicit changes in the EC50 values in the portal-systemic
collaterals of BDL rats in the current study, similar to
our previous finding in acute study.5 Apart from the
receptor-mediated vasoconstricting effect, the non-
receptor-mediated vasoconstriction on collaterals
induced by potassium chloride was not changed. The
lack of effect on baseline perfusion pressure for indo-
methacin observed in the present study has also been
reported in normal rat liver perfusion.33
In conclusion, chronic indomethacin administration
in BDL rats enhances the portal-systemic collateral
vascular responsiveness to AVP without modification
of the severity of portal-systemic shunting.
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